Clinical Trial: BiTE Antibody in Myeloma for Relapsed/Refractory Patients

Bi-specfic T-cell engages (also called BiTEs) are coming to myeloma clinical trials. BiTEs are artificial bispecific monoclonal antibodies which go after two targets - one on the T cell and one on the cancer cell. The antibody directs a patient's immune system (specifically the T cell) to link their T cells to the cancer cell, killing it. BiTE is a registered trademark of the company Micromet AG.

Specifically, the strong killing power of the T cell's CD3 receptor is connected with a specific protein that is found on the surface of myeloma cells. In the case of the BFCR4350A clinical trial, the T cell connects with a Fc receptor-like protein with five targets (FCRH5; CD307; FCRL5; IRTA2; BXMAS1). 

 This is a phase I, open-label, dose-escalation study of BFCR4350A administered as a single agent by IV infusion to participants with relapsed or refractory multiple myeloma. 

There are 6 active sites in the United States for this trial (Mayo Clinic Scottsdale, City of Hope, University of Colorado, Dana Farber, UPENN, Sarah Cannon). One site in Canada and another in Australia are also open. 

Learn more and connect with this trial directly at:

Clinical Trial

Find eligible clinical trials for your myeloma here:

Find all Clinical Trials